LXRX Stock Summary and Trading Ideas (Lexicon Pharmaceuticals | NASDAQ:LXRX)

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

Lexicon Pharmaceuticals trades on the NASDAQ stock market under the symbol LXRX.

As of September 9, 2026, LXRX stock price declined to $2.19 with 463,602 million shares trading.

LXRX has a beta of 0.36, meaning it tends to be less sensitive to market movements. LXRX has a correlation of 0.00 to the broad based SPY ETF.

LXRX has a market cap of $974.45 million. This is considered a Small Cap stock.

Last quarter Lexicon Pharmaceuticals reported $692,000 in Revenue and -$.07 earnings per share. This fell short of revenue expectation by $-4 million and missed earnings estimates by -$.02.

In the last 3 years, LXRX traded as high as $3.73 and as low as $.28.

The top ETF exchange traded funds that LXRX belongs to (by Net Assets): VTI, VXF, XPH, VTWO, SCHA.

LXRX has outperformed the market in the last year with a return of +102.8%, while the SPY ETF gained +18.9%. In the last 3 month period, LXRX beat the market returning +16.5%, while SPY returned +3.6%. However, in the most recent 2 weeks LXRX has underperformed the stock market by returning -6.4%, while SPY returned -0.3%.

LXRX support price is $2.16 and resistance is $2.30 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LXRX shares will trade within this expected range on the day.